These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481 [TBL] [Abstract][Full Text] [Related]
3. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443 [TBL] [Abstract][Full Text] [Related]
4. Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. Martino-Echarri E; Henderson BR; Brocardo MG Oncotarget; 2014 Oct; 5(20):9889-900. PubMed ID: 25301724 [TBL] [Abstract][Full Text] [Related]
5. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. Chen M; Mashima T; Oishi T; Muramatsu Y; Seto Y; Takamatsu M; Kawata N; Morino S; Nakamura A; Inaba S; Yuan X; Maruyama K; Suzuki M; Sato A; Yoshida H; Jang MK; Mizutani A; Takeuchi K; Yamaguchi K; Shirai F; Nagayama S; Katayama R; Seimiya H Br J Cancer; 2024 Jan; 130(1):151-162. PubMed ID: 37968472 [TBL] [Abstract][Full Text] [Related]
6. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Morino S; Mashima T; Shirai F; Nagayama S; Katayama R; Seimiya H Cancer Lett; 2024 Mar; 584():216632. PubMed ID: 38216082 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944 [TBL] [Abstract][Full Text] [Related]
8. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564 [TBL] [Abstract][Full Text] [Related]
9. Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract. Kim DY; Kwon YJ; Seo WY; Kim UI; Ahn S; Choi SM; Bang HT; Kim K; Kim JS Eur J Cancer; 2022 Sep; 173():41-51. PubMed ID: 35849876 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer. Zhang Y; Guo L; Li Y; Feng GH; Teng F; Li W; Zhou Q Mol Cancer; 2018 Jan; 17(1):1. PubMed ID: 29304823 [TBL] [Abstract][Full Text] [Related]
11. Survival of APC-mutant colorectal cancer cells requires interaction between tankyrase and a thiol peroxidase, peroxiredoxin II. Kang DH; Lee JHS; Kang SW BMB Rep; 2017 Aug; 50(8):391-392. PubMed ID: 28683851 [TBL] [Abstract][Full Text] [Related]
12. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Schell MJ; Yang M; Teer JK; Lo FY; Madan A; Coppola D; Monteiro AN; Nebozhyn MV; Yue B; Loboda A; Bien-Willner GA; Greenawalt DM; Yeatman TJ Nat Commun; 2016 Jun; 7():11743. PubMed ID: 27302369 [TBL] [Abstract][Full Text] [Related]
13. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition. Schatoff EM; Goswami S; Zafra MP; Foronda M; Shusterman M; Leach BI; Katti A; Diaz BJ; Dow LE Cancer Discov; 2019 Oct; 9(10):1358-1371. PubMed ID: 31337618 [TBL] [Abstract][Full Text] [Related]
14. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis. Christie M; Jorissen RN; Mouradov D; Sakthianandeswaren A; Li S; Day F; Tsui C; Lipton L; Desai J; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Burgess AW; Busam D; Zhao Q; Strausberg RL; Simpson AJ; Tomlinson IP; Gibbs P; Sieber OM Oncogene; 2013 Sep; 32(39):4675-82. PubMed ID: 23085758 [TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway. Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Tamir T; Jain V; Bharatam PV; Wyatt MD; Kundu CN DNA Repair (Amst); 2014 Dec; 24():15-25. PubMed ID: 25460919 [TBL] [Abstract][Full Text] [Related]
16. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517 [TBL] [Abstract][Full Text] [Related]
17. Targeted deep sequencing reveals Chen X; Hu M; Chen Y; Li A; Hua Y; Jiang H; Li H; Lin M Scand J Gastroenterol; 2022 Apr; 57(4):465-472. PubMed ID: 34978498 [No Abstract] [Full Text] [Related]
18. Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells. Kang DH; Lee DJ; Lee S; Lee SY; Jun Y; Kim Y; Kim Y; Lee JS; Lee DK; Lee S; Jho EH; Yu DY; Kang SW Nat Commun; 2017 Jun; 8(1):40. PubMed ID: 28659575 [TBL] [Abstract][Full Text] [Related]
19. Origin of Somatic Mutations in β-Catenin versus Adenomatous Polyposis Coli in Colon Cancer: Random Mutagenesis in Animal Models versus Nonrandom Mutagenesis in Humans. Yang D; Zhang M; Gold B Chem Res Toxicol; 2017 Jul; 30(7):1369-1375. PubMed ID: 28578586 [TBL] [Abstract][Full Text] [Related]